Pfizer (NYSE:PFE) Price Target Raised to $30.00

Pfizer (NYSE:PFE) had its target price raised by JPMorgan Chase & Co. from $28.00 to $30.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other analysts have also commented on the stock. Scotiabank lifted their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a report on Thursday. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. Five analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.72.

Pfizer Trading Down 0.0%

Pfizer stock opened at $28.27 on Friday. Pfizer has a one year low of $23.62 and a one year high of $29.21. The business’s fifty day moving average is $27.68 and its 200 day moving average is $26.50. The stock has a market capitalization of $161.14 billion, a PE ratio of 37.20, a price-to-earnings-growth ratio of 1.91 and a beta of 0.32. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. Pfizer’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts predict that Pfizer will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. HF Advisory Group LLC boosted its holdings in Pfizer by 7.8% during the 3rd quarter. HF Advisory Group LLC now owns 110,318 shares of the biopharmaceutical company’s stock valued at $3,146,000 after acquiring an additional 7,940 shares during the period. Gallagher Capital Advisors LLC increased its stake in Pfizer by 1.5% in the third quarter. Gallagher Capital Advisors LLC now owns 143,311 shares of the biopharmaceutical company’s stock worth $4,087,000 after purchasing an additional 2,069 shares during the period. Friday Financial purchased a new stake in Pfizer in the third quarter worth $222,000. Valley Wealth Managers Inc. lifted its position in shares of Pfizer by 2.1% during the third quarter. Valley Wealth Managers Inc. now owns 1,035,192 shares of the biopharmaceutical company’s stock worth $29,524,000 after purchasing an additional 21,005 shares during the last quarter. Finally, Atlas Brown Inc. lifted its position in shares of Pfizer by 1.9% during the third quarter. Atlas Brown Inc. now owns 82,433 shares of the biopharmaceutical company’s stock worth $2,351,000 after purchasing an additional 1,557 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst support improved: JPMorgan raised its price target from $28 to $30 while maintaining a neutral rating, and Jefferies issued a buy rating. Cantor Fitzgerald also increased its target to $28, signaling some potential downside protection at current levels.
• Positive Sentiment: TUKYSA approval expands Pfizer’s oncology opportunity: The FDA approved TUKYSA in combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for certain patients with HER2-positive metastatic breast cancer. Moving the drug into an earlier line of treatment could broaden its commercial reach. FDA Backs Pfizer’s TUKYSA Combination
• Positive Sentiment: Pipeline progress adds longer-term support: Pfizer’s Phase 3 trial of tilrekimig, an asthma candidate, is advancing. Investors are also focused on oncology sales, biosimilars and the late-stage pipeline ahead of quarterly results. Tilrekimig Phase 3 Trial Update
• Positive Sentiment: Income and valuation appeal remain catalysts: Pfizer’s dividend announcement, roughly 6% yield and valuation below many large pharmaceutical peers continue to attract income and value-oriented investors. The company also has a history of earnings beats, with its latest reported quarter exceeding consensus estimates for both earnings and revenue.
• Neutral Sentiment: Investor attention is elevated: Pfizer was among heavily searched stocks, while broader biotechnology interest was helped by Moderna’s Nasdaq-100 inclusion. These factors may increase trading activity but do not directly change Pfizer’s fundamentals.
• Negative Sentiment: High yield raises risk concerns: Commentary warns that Pfizer’s unusually large dividend yield may reflect investor doubts about earnings, cash flow, debt and the durability of the payout. Sluggish revenue growth, a thin net margin and relatively low return on equity reinforce those concerns. Pfizer Dividend Yield Analysis
• Negative Sentiment: Cost-cutting highlights operational pressure: Pfizer plans to close a penicillin unit in Italy and eliminate about 330 jobs, underscoring efforts to improve efficiency amid a challenging growth outlook. Pfizer Italy Penicillin Unit Closure

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.